VANINasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Vivani Medical, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.12+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $97.54M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2025
Gross margin
–
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -211.3% | -322.6% | -159.6% | |
| Return on assets | -147.3% | -141.3% | -65.7% | |
| Current ratio | 2.70 | 0.83 | 2.71 | |
| Inventory turnover | 1.7× | – | – | |
| Capex to revenue | 12.3% | – | – | |
| Diluted shares | 5M | 21M | 62M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Vivani Medical generated $98.54M from operations and spent $3.53M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$98.54M
Used
$3.53M
Capital expenditure$3.53M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-994.1%
×Asset turnover0.25×
×Equity multiplier2.63×
=Return on equity, FY2019-648.6%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2019 | -994.1% | 0.25× | 2.63× | -648.6% |
| FY2018 | -508.6% | 0.55× | 2.30× | -640.1% |
| FY2017 | -358.1% | 0.51× | 1.65× | -299.7% |
| FY2016 | -832.6% | 0.18× | 1.43× | -211.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$26.61M
- Cash generatingOperating cash flow above zero-$24.32M
- Return on assets improvedROA up on the prior year-51.3% → -64.0%
- Earnings backed by cashOperating cash flow above net income-$24.32M vs -$26.61M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.41 → 2.71
- No dilutionShare count did not rise55M → 62M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.00